A powerful committee in the U.S. Senate is considering legislation that could have significant negative effects on Mainers seeking treatment from cutting-edge drugs. The measure would remove the existing requirement that a biologic or biosimilar product sold in the U.S. adhere to public standards, called monographs, set by the U.S. Pharmacopeia (USP), an independent non-profit … Continue reading Congress should preserve public quality standards for biologic drugs